MURRAY HILL, N.J.--(BUSINESS WIRE)--C. R. Bard, Inc. (NYSE:BCR) today announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has approved a new technology add-on payment for the Lutonix® Drug-Coated Balloon (DCB) under the Medicare hospital inpatient prospective payment system. The purpose of the reimbursement is to help cover additional cost to U.S. hospitals for treating Medicare beneficiaries with the Lutonix® DCB in the inpatient setting. CMS determined the amount of the add-on payment to be a maximum of $1,036 when DCBs are used for inpatient peripheral procedures and the total device costs exceed the allowance for existing DRG reimbursement. The add-on payment is effective October 1, 2015.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
